Abstract Background IncobotulinumtoxinA (Xeomin®) is a botulinum neurotoxin type A with
established efficacy in the treatment of upper-limb spasticity in adults. This retrospective …

PURPOSE: Investigate the efficacy and safety of multipattern incobotulinumtoxinA injections
in children/adolescents with lower-limb cerebral palsy (CP)-related spasticity. METHODS …

Background This randomized, phase 3 study with double-blind main period (MP) and open-
label extension (OLEX; NCT02002884) assessed incobotulinumtoxinA safety and efficacy …

Background The only two preparations of botulinum toxin A for which there are published
evidences of efficacy in children with cerebral palsy are onabotulinum toxin A (Botox®) and …

Background IncobotulinumtoxinA (Xeomin®) is a purified botulinum neurotoxin type A
formulation, free from complexing proteins, with proven efficacy and good tolerability for the …

IncobotulinumtoxinA, a pure botulinumtoxinA formulation, is free of accessory proteins. This
analysis provides pooled safety data from phase 3 trials of children/adolescents (2–17 …

PURPOSE: The open-label phase 3 “Treatment with IncobotulinumtoxinA in Movement
Open-Label”(TIMO) study investigated longer-term safety and efficacy of …

BACKGROUND. Spasticity is a prevalent disabling clinical symptom for children with
cerebral palsy. Treatment of spasticity with botulinum toxin in children with cerebral palsy …

Abstract Intramuscular incobotulinumtoxinA (Xeomin®) is indicated for the treatment or
improvement of adult patients with upper limb spasticity (featured indication), cervical …

Botulinum toxin A is widely used for spasticity management in children with cerebral palsy,
although outcomes are unpredictable. The aim of this study was to identify criteria for …